Compare LOCO & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LOCO | OCGN |
|---|---|---|
| Founded | 1980 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 411.3M | 492.5M |
| IPO Year | 2014 | 2014 |
| Metric | LOCO | OCGN |
|---|---|---|
| Price | $13.81 | $1.29 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $14.17 | $9.75 |
| AVG Volume (30 Days) | 357.3K | ★ 5.9M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 4.65 | ★ 31.58 |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $401,701,000.00 | N/A |
| Revenue This Year | $3.60 | N/A |
| Revenue Next Year | $3.98 | $1,718.38 |
| P/E Ratio | $51.26 | ★ N/A |
| Revenue Growth | ★ 5.68 | N/A |
| 52 Week Low | $8.99 | $0.90 |
| 52 Week High | $15.90 | $2.73 |
| Indicator | LOCO | OCGN |
|---|---|---|
| Relative Strength Index (RSI) | 48.96 | 37.33 |
| Support Level | $13.52 | $0.99 |
| Resistance Level | $14.38 | $1.92 |
| Average True Range (ATR) | 0.49 | 0.06 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 19.18 | 15.62 |
El Pollo Loco Holdings Inc operates and franchises hundreds of fast-casual chicken restaurants in the United States. It specializes in fire-grilling citrus-marinated chicken and operates in the limited service restaurant market segment. Its offerings include Mexican-inspired menu items, including burritos, tostadas, bowls, salads, and bone-in chicken meals in various portion sizes. It also offers citrus-marinated fire-grilled chicken, along with a range of salsas and dressings that allow customers to customize their meals. The company operates in one operating segment. The majority of the company's revenue is derived from company-operated restaurant revenue.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").